Sfoungaristos, Stavros published the artcileNeoadjuvant chemotherapy prior to radical prostatectomy for patients with high-risk prostate cancer: a systematic review, Synthetic Route of 59973-80-7, the publication is Chemotherapy Research and Practice (2013), 386809, 7 pp., database is CAplus and MEDLINE.
High-risk prostate cancer represents a pretentious clin. problem since a significant number of its patients will relapse and progress after radical prostatectomy. Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have been used in high-risk patients prior to radical prostatectomy. Even though the results regarding the prognostic surrogates are not significant, the effects on clin. and pathol. outcomes are promising, while toxicity in most of the studies is in the expected field.
Chemotherapy Research and Practice published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C42H63O3P, Synthetic Route of 59973-80-7.
Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem